Article Text

PDF
Anti-vascular endothelial growth factor agents for diabetic maculopathy
  1. A Salam,
  2. J DaCosta,
  3. S Sivaprasad
  1. Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, Denmark Hill, London, UK
  1. Correspondence to Sobha Sivaprasad, Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, Denmark Hill, London SE5 9RS, UK; senswathi{at}aol.com

Abstract

The management of diabetic macular oedema is changing. The therapeutic armamentarium for diabetic macular oedema (DMO) includes a new group of drugs that inhibit vascular endothelial growth factor (VEGF). These anti-VEGF agents are already being used widely in DMO in clinical practice despite that several phase III trials on these drugs are still underway. There are no established protocols on the use of these agents in DMO, but short-term results are appealing. This review provides an update on the use of anti-VEGF agents in DMO. Although intravitreal delivery of anti-VEGF agents is a relatively safe procedure, the long-term local and systemic effects of these agents in the diabetic population remain unknown. In this regard, this review also highlights the need for close surveillance of the use of these drugs in this high-risk population.

  • Diabetic maculopathy
  • bevacizumab
  • ranibizumab
  • pegaptanib sodium
  • anti-VEGF
  • retina
  • macula
  • pharmacology
  • treatment other
  • clinical trial

Statistics from Altmetric.com

Footnotes

  • Competing interests Sobha Sivaprasad has received research grants from Novartis and Pfizer.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.